* Singular Genomics Systems Inc OMIC.OQ reported a
quarterly
adjusted loss of 34 cents per share for the quarter ended in
March, lower than the same quarter last year, when the company
reported EPS of -33 cents. The mean expectation of two analysts
for the quarter was for a loss of 35 cents per share.
* Revenue fell 48.8% to $442.00 thousand from a year ago;
analysts
expected $394.00 thousand.
* Singular Genomics Systems Inc's reported EPS for the
quarter was
a loss of 34 cents.
* The company reported a quarterly loss of $25.02 million.
* Singular Genomics Systems Inc shares had fallen by 16.8%
this
quarter and lost 7.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 4% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "hold."
Wall Street's median 12-month price target for Singular Genomics
Systems Inc is $0.85
This summary was machine generated from LSEG data May 14 at
10:44 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.35 -0.34 Beat
Dec. 31 2023 -0.34 -0.32 Beat
Sep. 30 2023 -0.38 -0.31 Beat
Jun. 30 2023 -0.37 -0.35 Beat